|
|
Article: Advancing Three Cancer Drugs, Salmedix Takes Aim At $86M IPO.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
As it works to develop effective drugs for blood cancers, Salmedix Inc. filed for an $86.25 million initial public offering less than a month after completing its Series C financing.
Founded in November 2000, the San Diego-based company plans to list its shares on the Nasdaq National Market under the symbol "SMDX."
New York-based SG Cowen Securities Inc. will serve as the sole book-running manager, with Pacific Growth Equities LLC and JMP Securities, both of San Francisco, and New York-based ThinkEquity Partners LLC serving as co-managers.
Salmedix officials are in an SEC-imposed quiet period and declined to comment ...